XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 Shares

XOMA Co. (NASDAQ:XOMA - Get Free Report) Director Joseph M. Limber acquired 17,935 shares of the stock in a transaction dated Thursday, April 3rd. The shares were bought at an average price of $25.24 per share, with a total value of $452,679.40. Following the completion of the purchase, the director now directly owns 16,524 shares of the company's stock, valued at approximately $417,065.76. This trade represents a -1,271.08 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

XOMA Stock Performance

Shares of XOMA stock traded up $0.27 on Friday, hitting $19.97. The company had a trading volume of 15,021 shares, compared to its average volume of 27,545. XOMA Co. has a twelve month low of $18.35 and a twelve month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market cap of $238.70 million, a P/E ratio of -5.74 and a beta of 1.00. The company has a 50-day moving average price of $22.14 and a 200-day moving average price of $26.20.

XOMA (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The company had revenue of $8.70 million during the quarter, compared to analysts' expectations of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. As a group, equities research analysts predict that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in XOMA. GAMMA Investing LLC grew its position in shares of XOMA by 1,063.8% during the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 1,585 shares during the period. BNP Paribas Financial Markets grew its holdings in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund increased its position in shares of XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after buying an additional 800 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of XOMA by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock worth $113,000 after buying an additional 1,183 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after buying an additional 2,009 shares in the last quarter. Hedge funds and other institutional investors own 95.92% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on XOMA shares. HC Wainwright reaffirmed a "buy" rating and set a $104.00 target price on shares of XOMA in a report on Friday, March 28th. StockNews.com upgraded shares of XOMA from a "sell" rating to a "hold" rating in a research note on Friday.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.